Prognostic value of reverse remodelling criteria in heart failure with reduced or mid-range ejection fraction
- PMID: 34002938
- PMCID: PMC8318429
- DOI: 10.1002/ehf2.13396
Prognostic value of reverse remodelling criteria in heart failure with reduced or mid-range ejection fraction
Abstract
Aims: Reverse remodelling (RR) is the recovery from left ventricular (LV) dilatation and dysfunction. Many arbitrary criteria for RR have been proposed. We searched the criteria with the strongest prognostic yield for the hard endpoint of cardiovascular death.
Methods and results: We performed a systematic literature search of diagnostic criteria for RR. We evaluated their prognostic significance in a cohort of 927 patients with LV ejection fraction (LVEF) < 50% undergoing two echocardiograms within 12 ± 2 months. These patients were followed for a median of 2.8 years (interquartile interval 1.3-4.9) after the second echocardiogram, recording 123 cardiovascular deaths. Two prognostic models were defined. Model 1 included age, LVEF, N-terminal pro-B-type natriuretic peptide, ischaemic aetiology, cardiac resynchronization therapy, estimated glomerular filtration rate, New York Heart Association, and LV end-systolic volume (LVESV) index, and Model 2 the validated Cardiac and Comorbid Conditions Heart Failure score. We identified 25 criteria for RR, the most used being LVESV reduction ≥15% (12 studies out of 42). In the whole cohort, two criteria proved particularly effective in risk reclassification over Model 1 and Model 2. These criteria were (i) LVEF increase >10 U and (ii) LVEF increase ≥1 category [severe (LVEF ≤ 30%), moderate (LVEF 31-40%), mild LV dysfunction (LVEF 41-55%), and normal LV function (LVEF ≥ 56%)]. The same two criteria yielded independent prognostic significance and improved risk reclassification even in patients with more severe systolic dysfunction, namely, those with LVEF < 40% or LVEF ≤ 35%. Furthermore, LVEF increase >10 U and LVEF increase ≥1 category displayed a greater prognostic value than LVESV reduction ≥15%, both in the whole cohort and in the subgroups with LVEF < 40% or LVEF ≤ 35%. For example, LVEF increase >10 U independently predicted cardiovascular death over Model 1 and LVESV reduction ≥15% (hazard ratio 0.40, 95% confidence interval 0.18-0.90, P = 0.026), while LVESV reduction ≥15% did not independently predict cardiovascular death (P = 0.112).
Conclusions: Left ventricular ejection fraction increase >10 U and LVEF increase ≥1 category are stronger predictors of cardiovascular death than the most commonly used criterion for RR, namely, LVESV reduction ≥15%.
Keywords: Criteria; Heart failure; Prognosis; Reverse remodelling.
© 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Conflict of interest statement
None declared.
Figures


Similar articles
-
Impact of Left Ventricular vs Biventricular Pacing on Reverse Remodelling: Insights From the Evaluation of Resynchronization Therapy for Heart Failure (EARTH) Trial.Can J Cardiol. 2017 Oct;33(10):1274-1282. doi: 10.1016/j.cjca.2017.07.478. Epub 2017 Jul 31. Can J Cardiol. 2017. PMID: 28941607 Clinical Trial.
-
The optimal definition and prediction nomogram for left ventricular remodelling after acute myocardial infarction.ESC Heart Fail. 2023 Oct;10(5):2955-2965. doi: 10.1002/ehf2.14479. Epub 2023 Jul 24. ESC Heart Fail. 2023. PMID: 37489064 Free PMC article.
-
Relationship between left ventricular dyssynchrony and reverse remodeling after cardiac resynchronization therapy.Clin Cardiol. 2011 Oct;34(10):645-8. doi: 10.1002/clc.20941. Epub 2011 Sep 12. Clin Cardiol. 2011. PMID: 21913208 Free PMC article.
-
Quality of life in patients with heart failure and improved ejection fraction: one-year changes and prognosis.ESC Heart Fail. 2022 Dec;9(6):3804-3813. doi: 10.1002/ehf2.14098. Epub 2022 Aug 2. ESC Heart Fail. 2022. PMID: 35916351 Free PMC article. Review.
-
Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure: An Individual Patient Data Meta-Analysis.Circulation. 2018 Jan 16;137(3):286-297. doi: 10.1161/CIRCULATIONAHA.117.031560. Circulation. 2018. PMID: 29335288
Cited by
-
Three-dimensional echocardiographic assessment of left ventricular geometric changes following acute myocardial infarction.Int J Cardiovasc Imaging. 2023 Mar;39(3):607-620. doi: 10.1007/s10554-022-02764-z. Epub 2022 Dec 6. Int J Cardiovasc Imaging. 2023. PMID: 36471104 Free PMC article.
-
Cardiac reverse remodelling by imaging parameters with recent changes to guideline medical therapy in heart failure.ESC Heart Fail. 2023 Dec;10(6):3258-3275. doi: 10.1002/ehf2.14555. Epub 2023 Oct 23. ESC Heart Fail. 2023. PMID: 37871982 Free PMC article. Review.
-
A review of biomarker and imaging monitoring to predict heart failure recovery.Front Cardiovasc Med. 2023 Apr 6;10:1150336. doi: 10.3389/fcvm.2023.1150336. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 37089891 Free PMC article. Review.
-
Can Right Heart Catheterization Improve the Prediction of Positive Response to Resynchronization Therapy?Biomedicines. 2025 Feb 14;13(2):467. doi: 10.3390/biomedicines13020467. Biomedicines. 2025. PMID: 40002881 Free PMC article.
-
Prediction of Left Ventricular Reverse Remodelling: A Mini Review on Clinical Aspects.Cardiology. 2022;147(5-6):521-528. doi: 10.1159/000526986. Epub 2022 Sep 14. Cardiology. 2022. PMID: 36103841 Free PMC article. Review.
References
-
- Aimo A, Gaggin HK, Barison A, Emdin M, Januzzi JL Jr. Imaging, biomarker, and clinical predictors of cardiac remodeling in heart failure with reduced ejection fraction. JACC Heart Fail 2019; 7: 782–794. - PubMed
-
- Koitabashi N, Kass DA. Reverse remodeling in heart failure—mechanisms and therapeutic opportunities. Nat Rev Cardiol 2011; 9: 147–157. - PubMed
-
- Halliday BP, Wassall R, Lota AS, Khalique Z, Gregson J, Newsome S, Jackson R, Rahneva T, Wage R, Smith G, Venneri L, Tayal U, Auger D, Midwinter W, Whiffin N, Rajani R, Dungu JN, Pantazis A, Cook SA, Ware JS, Baksi AJ, Pennell DJ, Rosen SD, Cowie MR, Cleland JGF, Prasad SK. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED‐HF): an open‐label, pilot, randomised trial. Lancet 2019; 393: 61–73. - PMC - PubMed
-
- Senni M, Parrella P, De Maria R, Cottini C, Böhm M, Ponikowski P, Filippatos G, Tribouilloy C, Di Lenarda A, Oliva F, Pulignano G, Cicoira M, Nodari S, Porcu M, Cioffi G, Gabrielli D, Parodi O, Ferrazzi P, Gavazzi A. Predicting heart failure outcome from cardiac and comorbid conditions: the 3C‐HF score. Int J Cardiol 2013; 163: 206–211. - PubMed
-
- Aimo A, Vergaro G, Castiglione V, Barison A, Pasanisi E, Petersen C, Chubuchny V, Giannoni A, Poletti R, Maffei S, Januzzi JL Jr, Passino C, Emdin M. Effect of sex on reverse remodeling in chronic systolic heart failure. JACC Heart Fail 2017; 5: 735–742. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical